CClinicalTrials.gg
Sign In
Status unknownNCT04445610Updated Jun 26, 2020

Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?

An observational study in Coronavirus (COVID-19), sponsored by Ain Shams University. Status unknown at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2020-06-26.

Sponsored by Ain Shams University · Observational

The sponsor has not verified this record recently (last verified Jun 2020), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
60
Sex
All
01

Study summary

The following two mechanisms that explain the ability of measles vaccine to cause partial protection against COVID-19. The first is that measles vaccine may increase the ability of the immune system to fight off pathogens other than measles due to the generated bystander immunity that would enhance the overall immunity against the new coronavirus. The second is that SARS-CoV-2 is proven to have structure similarities with measles, which may cause cross-reactivity and immunity between measles vaccines and COVID-19, leading to partial protection against COVID-19 in vaccinated subjects

Read the detailed description

Objectives:

  1. To identify Measles IgG titre in SARS-COV2 infected patients .
  2. correlate level of Measles IgG titre with the clinical severity of COVID-19 disease.

Secondary Objective To find an association of the postulated protective role of measles vaccine and SARS-COV2 infection

Criteria:

Inclusion criteria:included patients would be divided into 3 groups according to clinical severity of COVID-19 disease (mild ,moderate \& severe)

  • All patients with confirmed COVID 19 confirmed by positive PCR . .
  • Any age or gender.

Exclusion criteria:

  • Any patient refusing to be involved in the study.

Methods:

  • Informed consent will be taken from each subject
  • Full clinical examination.
  • Evaluation of Measles Antibody Titer:

The measles virus IgG antibody titer will be determined quantitatively by ELISA for quantitative determination of IgG class antibodies against Measles virus in human serum or plasma (citrate, heparin).

  • Anonymous data will be retrieved from the admitted patients' files, such as:
  • CBC, CRP, AST, ALT, ESR, Serum ferritin \& SARS CoV 2 RNA PCR swab results.
  • Chest X ray and/or CT chest.
02

Conditions studied

  • Coronavirus (COVID-19)

Browse trials for

03

In context

COVID-19

7,638 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's planned enrollment of 60 is below the median of 260 across 3,135 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

all patients with confirmed COVID-19 presented to Ain Shams Hospital

Inclusion criteria

  • All patients with confirmed COVID 19.
  • Any age or gender

Exclusion criteria

Exclusion Criteria:

    • Any patient refusing to be involved in the study
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • A

    mild

  • B

    moderate

  • C

    severe

06

What researchers measure

Primary outcomes

  1. Viral clearance

    Achievement of two consecutive negative PCR results for COVID 19 and discharge from hospital

    Time frame: 6 months

07

Study locations

1 site
  • Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center
    Cairo, Non-US 11566, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04445610
Lead sponsor
Ain Shams University
Responsible party
Amira Al Balakosy (Tropical Medicine Department. Ain Shams University, Ain Shams University) — Principal investigator
First posted
Jun 24, 2020
Start date
Jul 1, 2020 (estimated)
Primary completion
Sep 1, 2020 (estimated)
Completion
Nov 1, 2020 (estimated)
Last update
Jun 26, 2020

Study contacts

Amira Al Balakosy, MD
Contact
drbalakosy@gmail.com
01221977455
Amira Al Balakosy, M.D
principal investigator · Ain Shams University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

COVID-19→

Other studies from this sponsor

Ain Shams University

Start the discussion